Ambu (AMBU-B.CO) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $2.83B | Exchange | CPH |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | DK | CEO | Britt Meelby Jensen |
| IPO Date | 2004-02-11 | CAGR | 10.77% |
| Employees | 5,000 | Website | www.ambu.com |
| Div. Yield | 0.59% | Payout Ratio | 23% |
| Buy Back Yield | 0.8% | Total Yield | 1.39% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $2.86B | P/E | 39.09 | Forward P/E | 22.74 | PEG | -1.11 |
| P/S | 3.06 | P/B | 3.07 | P/CF | 22.15 | P/FCF | 36.26 |
| Sales | $931.65M | Sales 1Y | 4.63% | Sales 3Y | 32.35% | Sales 5Y | 59.29% |
| EPS | $0.27 | EPS 1Y | 28.99% | EPS 3Y | -792.34% | EPS 5Y | 58.63% |
| Sales QoQ | 0.96% | EPS QoQ | 2.27% | Sales QoQ Avg | 0.37% | EPS QoQ Avg | -9.28% |
| Gross Margin | 55.82% | Operating Margin | 10.71% | Profit Margin | 7.81% | ROCE | 9.95% |
| ROA | 6% | ROE | 8% | Altman Z Score | 9.67 | Piotroski Score | 6 |
| Current Ratio | 2.92 | Quick Ratio | 1.73 | Cash Ratio | 0.67 | Op. CF Ratio | 0.25 |
| Debt/Equity | 0.09 | Debt/Assets | 0.07 | Lt Debt/Equity | 0.08 | Lt Debt/Cap. | 0 |
| Intrst Cov. | 19.24 | Inventory Turnover | 2.19 | Asset Turnover | 0.8 | Receivables Turnover | 6.44 |
| Enterprise Value | $2.86B | P/E Ratio | 39.09 |
| Forward P/E | 22.74 | PEG Ratio | -1.11 |
| P/S Ratio | 3.06 | P/B Ratio | 3.07 |
| P/CF Ratio | 22.15 | P/FCF Ratio | 36.26 |
| EPS | $0.27 | EPS Growth 1Y | 28.99% |
| EPS Growth 3Y | -792.34% | EPS Growth 5Y | 58.63% |
| Revenue Growth 1Y | 4.63% | Gross Margin | 0.56% |
| Operating Margin | 0.11% | Profit Margin | 0.08% |
| ROE | 0.08% | ROA | 0.06% |
| ROCE | 0.1% | Current Ratio | 2.92 |
| Quick Ratio | 1.73 | Cash Ratio | 0.67 |
| Debt/Equity | 0.09 | Interest Coverage | 19.24 |
| Altman Z Score | 9.67 | Piotroski Score | 6 |
Ambu (AMBU-B.CO) valuation & financials
Ambu (AMBU-B.CO) has a market capitalization of 2.83B DKK and trades at a price-to-earnings ratio of 39.1. It operates in the Healthcare sector (Medical - Devices).
Ambu's revenue grew +4.6% over the last year.
Ambu's next earnings report is scheduled for August 26, 2026; analysts estimate EPS of 0.09 DKK.
Ambu (AMBU-B.CO) — frequently asked questions
When does Ambu (AMBU-B.CO) report earnings next?
Ambu is expected to report earnings on August 26, 2026. Analysts estimate EPS of 0.09 DKK.
What is Ambu's market cap?
Ambu (AMBU-B.CO) has a market capitalization of 2.83B DKK.
What is AMBU-B.CO's P/E ratio?
Ambu trades at a price-to-earnings ratio of 39.1, with trailing twelve-month EPS of 0.27 DKK.
How fast is Ambu growing?
Ambu's revenue grew +4.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)